JP2023537958A5 - - Google Patents

Info

Publication number
JP2023537958A5
JP2023537958A5 JP2023509554A JP2023509554A JP2023537958A5 JP 2023537958 A5 JP2023537958 A5 JP 2023537958A5 JP 2023509554 A JP2023509554 A JP 2023509554A JP 2023509554 A JP2023509554 A JP 2023509554A JP 2023537958 A5 JP2023537958 A5 JP 2023537958A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable domain
single variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023509554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537958A (ja
JP7821159B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/112756 external-priority patent/WO2022037527A1/zh
Publication of JP2023537958A publication Critical patent/JP2023537958A/ja
Publication of JP2023537958A5 publication Critical patent/JP2023537958A5/ja
Application granted granted Critical
Publication of JP7821159B2 publication Critical patent/JP7821159B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023509554A 2020-08-20 2021-08-16 Bcmaと結合する単一可変ドメイン及び抗原結合分子 Active JP7821159B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010842370.5 2020-08-20
CN202010842370 2020-08-20
PCT/CN2021/112756 WO2022037527A1 (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Publications (3)

Publication Number Publication Date
JP2023537958A JP2023537958A (ja) 2023-09-06
JP2023537958A5 true JP2023537958A5 (cg-RX-API-DMAC7.html) 2024-08-26
JP7821159B2 JP7821159B2 (ja) 2026-02-26

Family

ID=80323410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509554A Active JP7821159B2 (ja) 2020-08-20 2021-08-16 Bcmaと結合する単一可変ドメイン及び抗原結合分子

Country Status (6)

Country Link
US (1) US12612635B2 (cg-RX-API-DMAC7.html)
EP (1) EP4202047A4 (cg-RX-API-DMAC7.html)
JP (1) JP7821159B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230045066A (cg-RX-API-DMAC7.html)
CN (1) CN115715325A (cg-RX-API-DMAC7.html)
WO (1) WO2022037527A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230170721A (ko) * 2021-04-15 2023-12-19 치아타이 티안큉 파마수티컬 그룹 주식회사 Bcma를 표적으로 하는 다중 특이성 항체
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002238052A1 (en) * 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
US9243058B2 (en) * 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
BR112016024546A2 (pt) * 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
TWI700298B (zh) * 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
WO2019066435A2 (ko) 2017-09-29 2019-04-04 재단법인 목암생명과학연구소 Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
CN111542343B (zh) * 2018-08-24 2023-08-18 上海先博生物科技有限公司 抗bcma的单域抗体及其应用
CN109942708B (zh) * 2019-03-28 2021-01-05 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用
CN109942709B (zh) * 2019-04-22 2019-12-27 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
CN111333729B (zh) 2020-03-17 2022-12-06 深圳市南科生物工程有限公司 抗b细胞成熟抗原的纳米抗体及应用
KR20230170721A (ko) 2021-04-15 2023-12-19 치아타이 티안큉 파마수티컬 그룹 주식회사 Bcma를 표적으로 하는 다중 특이성 항체

Similar Documents

Publication Publication Date Title
JP2023526774A5 (cg-RX-API-DMAC7.html)
JP2019536430A5 (cg-RX-API-DMAC7.html)
JP2024167313A5 (cg-RX-API-DMAC7.html)
JP2021516976A5 (cg-RX-API-DMAC7.html)
JP2022502371A5 (cg-RX-API-DMAC7.html)
JP2023509196A5 (cg-RX-API-DMAC7.html)
JP2020525032A5 (cg-RX-API-DMAC7.html)
JP2021515566A5 (cg-RX-API-DMAC7.html)
JP2024062992A5 (cg-RX-API-DMAC7.html)
JP2020023523A5 (cg-RX-API-DMAC7.html)
JP2020506898A5 (cg-RX-API-DMAC7.html)
JP2020195399A5 (cg-RX-API-DMAC7.html)
WO2020114478A1 (zh) Cd3抗体及其药物用途
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2019501883A5 (cg-RX-API-DMAC7.html)
JP2020516309A5 (cg-RX-API-DMAC7.html)
JP2023543493A5 (cg-RX-API-DMAC7.html)
CN111201238B (zh) 产生多特异性抗体混合物及其使用方法
RU2010100638A (ru) Композиции и способы лечения, направленные против cd20
JPWO2015146437A1 (ja) 高機能性IgG2型二重特異性抗体
JP2018537421A5 (cg-RX-API-DMAC7.html)
WO2020114479A1 (zh) 多特异性蛋白分子
JP2021522303A5 (cg-RX-API-DMAC7.html)
WO2019196309A1 (zh) 抗pd-l1抗体及其用途
JPWO2020059847A5 (cg-RX-API-DMAC7.html)